All In Biotech

Drug Trial Radar · NCT04449874

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

498

Planned (sponsor's estimate)

Start

Jul 29, 2020

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Conditions

  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Advanced Solid Tumors

Interventions

  • GDC-6036Drug

    The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

  • AtezolizumabDrug

    A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.

  • CetuximabDrug

    Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.

  • BevacizumabDrug

    A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.

  • ErlotinibDrug

    150 mg of erlotinib will be administered PO QD in 21 day cycles.

  • GDC-1971Drug

    The starting dose of GDC-1971 will be determined from its single-agent dose escalation.

  • InavolisibDrug

    The starting dose of inavolisib will be determined from its single-agent dose escalation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AEs)Time frame: From Cycle 1 Day 1 until 28 days after the final dose (or as specified in the protocol). A cycle is 21 days.
  2. Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: From Cycle 1 Day 1 through Day 21. A cycle is 21 days.

Locations

63 sites in 17 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • UCSD Moores Cancer Center

    La Jolla, California

  • Chao Family Comprehensive Cancer Center UCI

    Orange, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Florida Cancer Specialists - Sarasota

    Sarasota, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • UPMC - Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Slade Health Inward goods

    Mount Kuring-Gai, New South Wales, Australia

  • Peter MacCallum Cancer Center

    Melbourne, Victoria, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • Linear Clinical Research Limited

    Nedlands, Western Australia, Australia

  • UZ Antwerpen

    Edegem, Belgium

  • CHU de Liège

    Liège, Belgium

  • AZ St Maarten Campus Leopoldstr

    Mechelen, Belgium

  • Instituto Nacional de Câncer

    Rio de Janeiro, Brazil

  • Santa Casa de Misericordia de Belo Horizonte - PPDS

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Clinicas de Porto Alegre HCPA PPDS

    Porto Alegre, Pará, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Universidade de Caxias do Sul

    Caxias do Sul, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS

    São José do Rio Preto, São Paulo, Brazil

  • Ottawa Hospital

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Clinexpert Gyongyos Kft

    Gyöngyös, Hungary

  • Rambam Medical Center

    Haifa, Israel

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS

    Meldola, Emilia-Romagna, Italy

  • Irccs Ospedale San Raffaele

    Milan, Lombardy, Italy

  • Asst Grande Ospedale Metropolitano Niguarda

    Milan, Lombardy, Italy

  • Istituto Clinico Humanitas

    Rozzano (MI), Lombardy, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Tuscany, Italy

  • The Aga Khan University-Kenya.

    Nairobi, Kenya

  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Auckland City Hospital, Cancer and Blood Research

    Auckland, New Zealand

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.